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Abstract.  Primary hyperoxaluria type 1 (PH  1), an in- 
born error of glyoxylate metabolism characterized by 
excessive synthesis of oxalate and glycolate, is caused 
by a defect in serine:pyruvate/alanine:glyoxylate 
aminotransferase (SPT/AGT).  This enzyme is per- 
oxisomal in human liver. Recently, we cloned SPT/ 
AGT-cDNA from a  PH 1 case, and demonstrated a 
point mutation of T  to C  in the coding region of the 
SPT/AGT gene encoding a Ser to Pro substitution at 
residue 205 (Nishiyama, K., T.  Funai,  R. Katafuchi, 
F. Hattori,  K.  Onoyama, and A. Ichiyama.  1991. Bio- 
chem.  Biophys.  Res.  Commun.  176:1093-1099).  In the 
liver of this patient,  SPT/AGT was very low with re- 
spect to not only activity but also protein detectable 
on Western blot and immunoprecipitation analyses. 
Immunocytochemically detectable SPT/AGT labeling 
was also low, although it was detected predominantly 
in peroxisomes. On the other hand,  the level of trans- 
latable SPT/AGT-mRNA was higher than normal,  indi- 
cating that SPT/AGT had been synthesized in the pa- 
tient's liver at least as effectively as in normal liver. 
Rapid degradation of the mutant SPT/AGT was then 
demonstrated in transfected COS cells and transformed 
Escherichia coli, accounting for the low level of im- 
munodetectable mutant SPT/AGT in the patient's liver. 
The mutant SPT/AGT was also degraded much faster 
than normal in an in vitro system with a rabbit 
reticulocyte extract,  and the degradation in vitro was 
ATP dependent.  These results indicate that a single 
amino acid substitution in SPT/AGT found in the PHI 
case leads to a reduced half-life of this protein.  It ap- 
pears that the mutant SPT/AGT is recognized in cells 
as an abnormal protein to be eliminated by degra- 
dation. 
S 
:e  RI  N~:pyruvate/alanine :glyoxylate  aminotransferase 
(EC 2.6.1.51/EC  2.6.1.44,  SPT/AGT) ',2 is an enzyme 
whose organelle localization and hormone responsive- 
ness differ with the animal  species.  In the liver of herbiv- 
orous animals,  including man, this enzyme is peroxisomal, 
while in carnivores  it is entirely  or largely  mitochondrial 
(Noguchi and Takada,  1978;  Takada and Noguchi,  1982; 
Danpure et al.,  1990).  In rat liver, SPT/AGT is located in 
both peroxisomes and mitochondria, and only the mitochon- 
drial enzyme is markedly induced by glucagon (Noguchi et 
al., 1978; Oda et al., 1982). It is well known that in eukary- 
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1. Abbreviations used in this paper:  PH 1, primary hyperoxaluria type 1; 
SPT/AGT,  serine:pyruvate/alanine:glyoxylate aminotransferase. 
2. This enzyme has been called serine:pyruvate aminotransferase (SPT, EC 
2.6.1.51)  or alanine:glyoxylate aminotransferase (AGT,  EC 2.6.1.44),  and 
both the activities have been assumed to be of physiological importance. 
In this paper, this enzyme is referred to as SPT/AGT. 
otic cells each  organelle  participates  in  different  cellular 
processes, and proteins involved in these processes are syn- 
thesized, predestined to be localized in a relevant subcellular 
compartment. Therefore,  the peroxisomal and/or mitochon- 
drial localization  of SPT/AGT suggests that the enzyme in 
the different  organeUes participates  in  different  metabolic 
processes. With respect to the mechanism  of directing  SPT/ 
AGT to either one of the two organelles  in rat liver, we re- 
cently demonstrated that transcription  of a single SPT/AGT 
gene from different initiation sites in exon 1 eventually deter- 
mines the alternative  targeting  of the expression product to 
either peroxisomes or mitochondria (Oda et al., 1990; Yokota 
et al.,  1991; Mori et al.,  1992). 
Primary hyperoxaluria  type 1 (PH 1), an inborn error of 
glyoxylate  metabolism characterized  by increased oxalate 
production,  has  been  shown  to be caused by a  defect  in 
SPT/AGT  in peroxisomes in the liver (Danpure  and  Jen- 
nings,  1986). This indicated that an important physiological 
role  of peroxisomal  SPT/AGT  is  to  remove  glyoxylate, 
preventing excessive production of oxalate, the injurious end 
product of metabolism. Glyoxylate is an immediate  precur- 
sor of oxalate and is produced mainly in peroxisomes in the 
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ganelle targeting, phenotypes of cell biological interest are 
also observed in the deficiency of  this enzyme in PH 1. Three 
phenotypic subgroups  of PH  1 have been  reported.  The 
majority of PH 1 patients have nearly complete deficiencies 
of SPT/AGT catalytic activity and SPT/AGT immunoreac- 
tive protein, but approximately one-third belonging to the 
second phenotypic subgroup possess significant levels of re- 
sidual SPT/AGT activity and immunoreactive protein (Wise 
et al., 1987; Danpure and Jennings, 1988; Danpure, 1991). 
In the latter case, it has been reported that the disease ap- 
pears to be due, at least in part, to a unique protein traffick- 
ing defect in which SPT/AGT is erroneously routed to the 
mitochondrion instead of its normal intracellular location, 
the peroxisome (Danpure et al., 1989). Among patients with 
zero SPT/AGT activity, there is another subgroup which has 
immunoreactive SPT/AGT correctly located within the per- 
oxisomes (Takada et al.,  1990;  Purdue et al.,  1992). 
We recently studied a PH 1 case who had had recurrent 
urinary calculi since the age of 6, reached the end-stage renal 
failure at age 39, which necessitated hemodialysis, and died 
at age 46. We cloned SPT/AGT-cDNA from the PH 1 case, 
and demonstrated a point mutation of T to C at position 613 
(relative to A of the initiation ATG codon) encoding a Ser 
to Pro substitution at residue 205.  The T to C conversion 
created a new SmaI site, which enabled us to demonstrate 
that the mutation occurs in the patient's gene (Nishiyama et 
al., 1991). In the liver of this patient, not only the SPT/AGT 
activity but also the protein detectable on Western blot and 
immunocytochemical analyses  was  low,  but  translatable 
SPT/AGT-mRNA  was  clearly  detectable.  In  the  present 
study, we demonstrated that the mutant SPT/AGT is unstable 
in cells and cell extracts, and decomposes much faster than 
normal.  Although the biological and pathological impor- 
tance of intracellular degradation systems to eliminate mis- 
folded proteins has long been suspected, this is one of the 
still relatively few cases in which rapid degradation of mu- 
tant protein is demonstrated in a hereditary disease. 
Materials and Methods 
Liver Samples 
Liver specimens obtained on autopsy 5-h postmortem from patients fie- 
male, 29 y, and male, 68 y) who died of other diseases and the PH 1 patient 
were immediately frozen in dry ice and stored at -80°C, as described previ- 
ously (Nishiyama et al.,  1991). 
RNA Blot Analysis 
RNA  blot  analysis was  performed according to  Alwine et  al.  (1977). 
Poly(A)-rich RNA was prepared from the PH 1 liver after extraction by the 
acid  guanidinium thiocyanate-phenol-chloroform method (Chomczynski 
and Sacchi, 1987).  Control poly(A)-rich RNA was prepared from a liver 
specimen otained on autopsy approximately 5-h postmortem from a patient 
(29 y, female) who died of a malignant lymphoma. The denatured RNA (5 
#g) was electrophoresed on a  1.2%  agarose gel and then transferred to a 
nylon membrane (Hybond-N; Amersham International Pie, Buckingham- 
shire,  England).  A  32P-labeled  120-bp  NcoI-HpaII fragment of human 
SPT/AGT cDNA (pHsptl2; Nishiyama et al., 1990) was used as a hybrid- 
ization probe. 4 mo later, ~-actin mRNA on the same nylon membrane was 
determined as an internal standard using a 443-bp Hint-Hint fragment of 
human ~-actin genomic DNA (hHal60; Nakajima-Iijima et al., 1985). Both 
DNA fragments were labeled by the random primer-labeling method (Fein- 
berg and Vogelstein, 1983)  with [tx-a2p]dCTP.  Prehybridization and hy- 
bridization were performed at 55°C for 20 h  in 5x  NaCI/Pi/EDTA  (Ix 
NaC1/Pi/EDTA:  0.18 M NaC1,  10 mM sodium phosphate [pH 7.4],  and 1 
mM EDTA)  containing 5×  Denhardt's solution (Maniatis et al.,  1982), 
0.5%  (wt/vol) SDS, and  100 #g/ml denatured salmon sperm DNA.  The 
membrane was washed twice with 5×  NaCI/Pi/EI3q'A for 15 rain each at 
55"C, twice in lx NaC1/Pi/EDTA  containing 0.1% (wt/vol) SDS for 10 rain 
each at 55°C, and finally twice in 0.1X  NaCI/Pi/EDTA containing 0.1% 
(wt/vol) SDS for 15 rain each at room temperature. 
In Vitro Translation 
RNA was synthesized in vitro from SPT/AGT eDNA clones isolated from 
control human liver (pHsptl2) (Nishiyama et al., 1990) or the patient's liver 
(pHOspt2) (Nishiyama et al., 1991) using T7 RNA polymerase (Melton et 
al.,  1984).  Linealized template DNA (5 #g) was transcribed at 37°C for 
5.5  h  with 20  U  of T7  RNA polymerase (New England Biolabs, Inc., 
Beverly,  MA) in the presence of 10 mM DTT, 0.5 mM each of ATP, CTE 
and  UTP,  0.05  mM  GTE  0.5  mM  PJ-5'-(7-methyl)-guanosine-p3-5  '- 
guanosine triphosphate (m:G[5~JPPP[5']G)  (New England Biolabs, Inc.), 
and 40 U of human placental RNase inhibitor (Takara  Shuzo Co., Ltd., 
Kyoto, Japan) in 40 mM Tris-HCl (pH 7.5) containing 6 mM MgC12, 2 
mM spermidine, and 0.01% (wt/vol) BSA, in a final volume of 50 #1. RNA 
formed was extracted sequentially with phenol and chloroform, precipitated 
with  ethanol,  dried,  and  then  dissolved  in  20  #1  of diethyl  pyrocar- 
bonate-treated water. 
Poly(A)-rich RNAs obtained from control liver and the patient's liver 
(1-t~g each) or RNA synthesized in vitro as above were translated in a reticu- 
locyte lysate system in the presence of L-[aSS]methionine as described pre- 
viously (Oda et al.,  1981). The translation products were immunoreacted 
with rabbit anti-rat mitochondrial SPT/AGT serum or rabbit nonimmune 
serum, and then precipitated by adsorption to Staphylosorb (Mercian Co., 
Tokyo, Japan). SDS/10% PAGE of the precipitates and fluorography were 
carried out as previously described (Oda et al.,  1981). 
Construction of  Human SPT/AGT 
Expression Plasmids 
For expression in COS-1  cells, an EcoRI-EcoRI fragment of pHsptl2 or 
pHOspt2 (full-length SPT/AGT cDNAs containing EcoRI linkers at their 
5' and 3' ends) was blunted with Klenow enzyme, and then directly intro- 
duced into a eukaryotic expression vector, pSVL, at the blunted Xhol site. 
The resultant recombinant plasmids were proliferated in Escherichia coli 
DH5~, and covalently closed circular plasmid DNAs were obtained by equi- 
librium  centrifugation in  cesium chloride-ethidium bromide gradients. 
They were designated as pSVLNOR for normal SPT/AGT and pSVLPH for 
the patient's SPT/AGT. 
For expression in E.  coli strain JMI05 cells, a prokaryotic expression 
vector, pKK233-2,  was digested with HindliI, blunted with Klenow en- 
zyme, and then cut with NcoI. An EcoRI-EcoRI fragment of pHsptl2 or 
pHOspt2 was blunted with Klenow enzyme and then cut at the Ncol site. 
The NcoI cleavage was carried out to shorten the 5:noncoding region of 
SPT/AGT eDNA to allow its efficient  transcription in E. coll. After the Ncol 
cleavage,  the ATG sequence in the NcoI site remained on the coding side 
of SPT/AGT-cDNA as the initiation ATG codon. The resultant SPT/AGT 
eDNA fragments were inserted into linealized pKK233-2 by ligation of  both 
the NcoI cohesive terminal and the blunt-ended terminal. The constructed 
recombinant plasmids were designated as pKKNOR for normal SPT/AGT 
and pKKPH for the patient's SPT/AGT. 
Expression of  Human SPT/AGT in COS Cells 
and E. coli 
COS-1 cells were transfected with pSVLNOR or pSVLPH by electropora- 
tion as described previously (Yokota et al., 1991), except that 30 #g of the 
purified recombinant plasmids was cotransfected with 4 #g of pCHll0, a 
plasmid containing a functional lac Z gene which is expressed from the SV- 
40 early promoter, pCHll0 was used as an internal standard for monitoring 
the efficiency of the transient expression. The transfected cells were plated 
on 35-mm dishes and allowed to grow at  37°C  for 48 h  in DME  sup- 
plemented with 10% (vol/vol) FCS, with a medium change at 12 h. The ly- 
sate of COS-1  cells was prepared as described previously (Yokota et al., 
1991), except that the lysis buffer comprised 50 mM Tris-HCl (pH 8.0),  150 
mM NaC1, 1% (vol/vol) Triton X-100, 1 mM PMSF, 1/~g/ml aprotinin, and 
0.02%  (wt/vol) sodium azide. 
E. coil JM105 was transform~l with pKKNOR or pKKPH according to 
Hanahan (1983). 200 ml of M9CA medium (Maniatis et al., 1982) contain- 
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inoculated with an overnight culture of E. coli JM105 transformed with one 
of the recombinant plasmids, followed by incubation at 37°C with shaking. 
When the absorbance at 600 tun reached 0.6, chlorampbenicol was added 
to a final concentration of 68/zg/ml, and then the incubation at 37°C was 
continued overnight. Cells were collected by centrifugation (5,000 g for 10 
min at 4°C),  washed with M9CA medium, and suspended in 50 ml of 
M9CA medium containing 50/~g/rrd ampicillin,  10/~g/ml streptomycin, 
and 1/~g/ml thiamine. After incubation for 1 h at 37°C, ceils were exposed 
to 1 mM isopropyi-l-thio-/~-l)-galactopyranoside  for 18 h at 37°C to induce 
transcription from the trc promoter, and then immediately chilled in ice and 
harvested by centrifugation (5,000 g  at 4°C for 10 rain). The pellet was 
washed with 0.5%  (wt/vol) NaCI/0.5%  (wt/vol) KCI, and then suspended 
in 40 ml of 50 mM potassium phosphate buffer (pH 7.2) containing 0.1 mM 
pyridoxal 5~phosphate,  1 mM pyruvate, 1 mM PMSF, and 10/~g/ml tmns- 
epoxy succinyl-L-leucylamido(3-methyl)botane (E-64C,  a  thiol protease 
inhibitor). The suspension was sonicated for 5 rain at 200 W using an Inso- 
nator (model 200 M; Kubota Manufacturing Co., Tokyo, Japan), and the 
lysate was clarified by centrifugation (14,800 g at 4°C for 10 rain). A portion 
of the E. coli suspension was centrifuged without sonication, and the pellet 
was dissolved in the SDS-gel loading buffer, immediately boiled for 5 rain, 
and subjected to SDS-PAGE. 
Preparation of  a Liver Extract 
A control human liver and the patient's liver 0  g each) were homogenized 
with 5 vol of extraction buffer (50 mM Hepes [pH 7.4],  150 mM NaCI,  1 
mM EDTA, 50 #M pyridoxai 5~phosphate,  0.02 % (wt/vol) sodium azide, 
and 1% (vol/vol) Triton X-100 containing 1 mM PMSE 1/zg/ml aprotinin, 
1 ~g/ml antipain, 0.7 t~g/ml pepstatin A, 1 #g/ml leupeptin, and 10/~g/rnl 
E-64C) in a Potter-Elvehjem homogenizer in an ice bath. A sonicated ex- 
tract was then prepared from each liver homogenate by sonication using an 
Insonator (model 200 M; 200 W for 15 rain in the cold), followed by cen- 
trifugation at  14,800  g for 10 rain at 4°C. 
Western Blot Analysis 
A polyclonal antibody against human SPT/AGT was raised in a white New 
Zealand rabbit (male) weighing 1.5 kg by subcutaneous injection of 0.1 mg 
of the purified enzyme in complete Freund's adjuvant by the method of Dun- 
bar and Schwoebel (1990).  3 wk and 6 wk later, the rabbit was again im- 
munized with 0.05 mg of the antigen in incomplete Freund's adjuvant. Pre- 
immune serum was obtained just before the first injection of the antigen. 
Antiserum was obtained 8 wk after the first injection. 
Western blot analysis was performed with human liver sonicated extract 
(10/zg protein), COS-1 cell lysate (100/zg protein), E. coli JM105 sonicated 
extract (37.5/zg protein), or E. coli JM105  lysate from equivalent volume 
of cell suspension to that used for the preparation of sonicated extract, es- 
sentially according to Kruger and Hammond (1988),  using t25I-labeled pro- 
tein A. Briefly,  electrophoresis was carried out in an SDS/12% polyacryl- 
amide gel, and then the gel was soaked in 25 mM Tris/192 mM glycine/15 % 
(vol/vol) methanol (pH 8.25) for 30 min, followed by electxophoretic trans- 
fer (2 mA/cm  2, for 2 h) to an Immobilon Transfer Membrane (Nihon Mil- 
lipore Ltd., Tokyo, Japan). The membrane was incubated at room tempera- 
ture for 1 h in a blocking buffer comprising 5% (wt/vol) nonfat dried milk 
and 0.05 % (vol/vol) Tween 20 in PBS, and then placed in diluted rabbit 
anti-human SPT/AGT serum (1:1,000) in the blocking buffer at 4°C for 16 h 
with gentle rotation. After washing five times for 10 rain each with PBS, 
the membrane was incubated at room temperature in 20 nil of PBS contain- 
ing 4% (wt/vol) BSA and 37 kBq of 125I-labeled protein A for 2 h. After 
washing five times for 10 rain each with PBS containing 1% (vol/vol) Triton 
X-100,  the membrane was dried and subjected to autoradiography using 
x-ray film and an intensifying screen. 
Immunoprecipitation of  Human SPT/AGT 
Immunoprecipitation  of  human SPT/AGT was carried out using anti-human 
SPT/AGT  serum  and  Staphylosorb  or  Pansorbin  Cells  (Calbiochem- 
Behring Corp., Ida Jolla, CA) according to Sambrook et al. (1989).  Soni- 
cared extracts from human livers and E. coli JM105 cells, and a lysate of 
COS-1  cells were incubated at 4°C for 10 min with 50/zl of 10% (wt/vol) 
Staphylosorb or 40 t~l of 10%  (wt/vol) Pansorbin cells in NET-gel buffer 
(50 mM Tris-HCl [pH 7.5] containing 150 mM NaCl, 0.1% [vol/vol] NP-40, 
1 mM EDTA [pH 8.0], 0.25% [wt/vol] gelatin, and 0.02%  [wt/vol] sodium 
azide) with gentle rocking, in a final vol of 350/~1 (in case of Staphylosorb) 
or 340/zl (in case of Pansorbin cells). After centrifugation (14,800 g at 4°C 
for 5 min), supernatants were incubated at 4°C for 2 h with anti-human 
SPT/AGT serum in NET-gel buffer, and then 10% (wt/vol) Staphylosorb or 
Pansorbin cells were added and the incubation was continued at 4°C for 1 h 
with gentle rocking.  The amounts of anti-human SPT/AGT  serum and 
Staphylosorb or Pansorbin cells used in each experiment are given in the 
legends to the figures. The immune complex adsorbed on Staphylosorb or 
Pansorbin cells was washed by vigorous vortexing for 2 rain each first with 
NET-gel buffer containing 0.5 M NaCl, then with NET-gel buffer containing 
0.1%  (wt/vol) SDS and finally with 10 mM Tris-HC1  (pH 7.5) containing 
0.1% (vol/vol) NP-40.  Denaturation of the proteins in the immunoprecipi- 
tate and analysis by SDS/12% PAGE were performed as described previ- 
ously (Oda et al., 1981). In a preliminary experiment in which [35S]methi- 
onine-labeled SPT/AGT  in the COS-1  cell lysate (850  #g protein) was 
immunoprecipitnted using 50 #1 of 10% (wt/vol) Staphylosorb, essentially 
the  same radioactivity was  recovered in  the 43-kD  band  (representing 
SPT/AGT) with any amount of anti-human SPT/AGT serum between 1 and 
100 #1. 
Pulse-Chase Experiment 
Experiment with COS-1 Cells.  COS-1  cells transfected with pSVLNOR 
or pSVLPH were cultured for 48 h as described above, and then washed 
twice with 2 ml of  prewarmed (370C) methionine-free  DME. The cells were 
further incubated for 20 rain at 37°C in 2  mi of methionine-free DME, 
followed by pulse-labeling with 740  or  1,110 kBq  (20  or  30  pmol) of 
Expre3sS35S  protein  labeling  mix  (a  mixture  of  [35S]methionine  and 
[3SS]cysteine) for 20 min at 37°C in 0.5 ml of fresh methionine-free DME. 
The  cells were then washed twice with prewarmed (37°C)  DME  sup- 
plemented with 10% (vol/vol) FCS, to which unlabeled L-methionine and 
L-cysteine were added to 225/~g/ml and 375 t~g/ml, respectively, and in- 
cubated at 37°C in 2 ml of the same medium for various periods of time. 
The incubated cells were washed with PBS, stored at  -80°C, and lysates 
were prepared as described above. 
Experiment  with E.  coil  JMI05  Cells.  E.  coli JM105  cells bearing 
pKKNOR or pKKPH were cultured overnight in a  small scale (2 ml of 
medium) as described above, and then washed twice with 1 ml each of 
M9CA medium supplemented with a mixture of all the L-amino acids (ex- 
cept methionine) at 20/~g/ml each, 50/zg/ml ampicillin, 10 #g/m1 strep- 
tomycin, and 1/~g/ml thiamine. The washed cells were suspended in 0.6 ml 
of  the same medium and incubated for 10 rain at 37°C, and then isopropyl-1- 
thio-/~q)-galactopyranoside was added to 1 mM to induce the transcription 
of transfected pKKNOR and pKKPH. After incubation with shaking for 30 
min at 37°C, 1.85 MBq (50 pmol) of L-[aSS]methionine was added and the 
incubation was continued for additional 5  rain.  Unlabeled L-methionine 
was then added to 100 #g/ml, and 100-#1 aiiquots of the cell suspension 
were incubated in separate Eppendorf tubes (Brinkman Instruments Inc., 
Westhury, NY) for various periods of time with shaking at 37°C. The cells 
were harvested, washed with M9CA medium, resuspended in  100/~l of 
M9CA medium, and stored frozen in dry ice until all the samples were 
ready for sonication. The cell suspension was then sonicated in an Eppen- 
doff tube three times for 10 s each at 8 W  with the aid of an Ultrasonic 
Processor (model 7040; SEIKO Instruments & Electronics Ltd., Tokyo, Ja- 
pan), and resultant sonicated extract was subjected to the reaction with 
anti-human SPT/AGT serum. 
Degradation In Vitro with Rabbit Reticulocyte Extract 
35S-labeled  normal and mutant human SPT/AGT were synthesized from 
respective cDNAs in a "1"7 RNA polymerase-reticulocyte lysate system es- 
sentiaily as described above, with following changes, pAM19 containing 
EcoRI-EcoRI  fragment  of pHsptl2  or  pHOspt2  was  lineafized  with 
BamHI, purified by treatment with 100/zg/ml proteinase K for 30 rain at 
37°C in the presence of 0.5% SDS and used as template DNA. Spermidine 
was omitted from the transcription buffer,  and after the transcription, the 
template DNA was digested with 300/~U/ml of RNase-free DNase I (Phar- 
macia, Uppsala, Sweden) for 15 min at 37°C. The concentration of synthe- 
sized RNA was determined spectrophotometrically by absorption at 260 
nm,  and the size of the RNA was  checked by electrophoresis through 
agarose gel. A 0.2-/zg aliquot of the RNA formed was translated for 90 min 
at 25°C with 10/zl of rabbit reticulocyte lysate for in vitro translation, in 
the  presence  of  1.85 MBq  of Expre35S3sS  protein  labeling  mix  in  a 
methionine-free  translation cocktail (Mori et al., 1979),  in a final vol of 25 
/~1. The translation was stopped by adding 40/~g/ml of cycloheximide and 
5  mM  each  of L-methionine and  L-cysteine.  The  degradation of 35S- 
labeled SPT/AGT was then followed in a reaction mixture comprising 3 #1 
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td of rabbit reticulocyte extract for protein degradation in 50 mM Tris-HCl 
(pH 7.8), in a  final  volume of 60 #l.  When energy requirement of the 
SPT/AGT degradation was to be examined, ATP was omitted from the reac- 
tion mixture,  and 20 mM 2-deoxyglucose  and 25 U/ml of hexokinase were 
added. After incubation at 37°C for various periods of time, a l(Y/~l  aliquot 
of the reaction mixture was removed, mixed with 20/~l of SDS-gel loading 
buffer, and immediately  boiled for 5 rain. One half of the sample was then 
subjected to SDS/10 % PAGE  and autoradiography for estimation of the ra- 
dioactivity  in the 43-kD band. 
Immunocytochemical Staining of  Human SPT/AGT 
Preparation of 1Issues.  Frozen tissue blocks of biopsy and autopsy liver 
samples  were put into ice-cold  fixative I, that consisted  of 4%  (wt/vol) 
paraformaldehyde  (Merck, Darmstadt, Germany), 0.2 % (vol/vol) glutaral- 
dehyde  (Nacalai  Tesque Inc., Kyoto, Japan), 0.01% (wt/vol)  CaC12, and 
0.15 M cacodylate-HCl  buffer (pH 7.4) (Yokota,  1990),  and then slowly 
thawed.  The tissue blocks were  embedded on the specimen folder of a 
Vibratome (Oxford Labs., City, CA) in agarose, cut into 200-/~m thick sec- 
tions in a trough filled with fixative I, and then fixed for 2 h at 4°C.  The 
sections were cut into about 1 mm x  1 nun cubes and divided into three 
groups.  The first and second groups were fixed again in 2% (vol/vol) glu- 
taraldehyde  in 0.1 M cacodylate-HC1  (pH 7.4) buffer for 1 h at 4°C.  The 
third group was further fixed in fixative I for an additional 1 h at 4"C. The 
first  group was  then postosmicated with  1%  (wt/vol)  reduced  osmium 
tetroxide,  dehydrated  in a  graded ethanol series,  and then embedded in 
Epon (TAAB, London, England). The second group was stained for cata- 
lase by means of the alkaline diaminobermidine  reaction (LeHir et al., 
1979), postosmicated, dehydrated,  and then embedded in Epon. The third 
group was dehydrated in a graded dimethylformamide series and then em- 
bedded in LR White (Nippon Bio-Rad Laboratories, K. K., Tokyo, Japan) 
at -20°C. Polymerization  of LR White was carried out under UV light at 
-20°C for 24 h (Yokota, 1990), Ultra-thin sections were cut with an LKB 
Ultrotome (LKB, Broma, Sweden)  equipped  with a diamond knife.  Thin 
sections  of the first group were used for morphological observation. Di- 
aminobenzidine staining of peroxisomal  catalase was observed using thin 
sections  of the second group. 
Iramunoelectron Microscopic Procedures.  Thin sections from the third 
group were mounted on uncoated nickel grids. Imrnunostaining  procedures 
were based on the method of Roth (1982). The sections were incubated in 
1% (wt/vol) BSA for 5 rain. This was followed by overnight incubation with 
50 #g proteirdml each of anti-human SPT/AGT serum, anti-rat mitochon- 
drial SPT/AGT serum, anti-rat liver catalase serum or nonimmune serum 
at 4°C. After washing with PBS, the sections were incubated with a protein 
A-gold probe (15 nm in diameter) for 30 rain at room temperature.  The sec- 
tions were then washed with distilled water, air-dried, and contrasted with 
2% (wt/vol) uranyl acetate for 3 rain and with 4% (wt/vol) lead citrate for 
20 s. After carbon coating,  the sections  were examined  under a Hitachi 
H600 electron microscope at an accelerating voltage of 75 kV. To evaluate 
the intracellular labeling density distribution, 10 micrographs of bepato- 
cytes were taken. The surface areas of the paroxisomes,  mitochondria, and 
cytoplasm in the positive  pictures,  enlarged to a  final  magnification  of 
40,000, were estimated with a semi-computing  system, and then the number 
of gold particles on each area was determined (Yokota, 1986). The labeling 
density was expressed  as the number of gold particles per square micron 
(Bendayan et al.,  1980). 
Other Methods 
RNA was determined spectrophotometrically  with the assumption that an 
absorbance reading of 1.0 at 260 nm corresponds to a concentration of 40 
~g/ml. The  /3-galactosidase  activity  used  to  monitor the  transfection 
efficiency  was  assayed  using a  TKO-100  Dedicated  Mini Fluorometer 
(Hoefer Scientific Instruments, San Francisco,  CA) essentially according to 
a technical bulletin for the/~-galactosidase  assay by use of the fluorometer 
(contributed by W. A. Braell). The reaction mixture comprised 160 ttl of 
a  reaction cocktail (25 mM Tris-HC1 [pH 7.5],  125 mM NaCl,  2  mM 
MgC12,  12  mM  /~-mercaptoethanol,  and  0.3  mM  4-methylumbelli- 
feryl-#-o-galactoside)  and 40 #1 of COS-1 cell lysate (20 #g protein). The 
reaction was carried out at 37"C for 30 min and was stopped by adding 50 
#1 of 25 % (vol/vol) TCA, followed by cooling on ice. The samples were cen- 
trifuged for 2 rain at room temperature in an Eppendorf microfuge.  The 
resulting supernatant (100 t~l) was added to 2 ml of glycine-earbonate ro- 
agent (133 mM glycine  and 83  mM Na2CO3 IpH  10.7]), and then the 
fluorescence  (excitation  at 380 nm, emission at 460 nm) was read with a 
TKO-100 Mini Fluorometer (Hoefer  Scientific  Instruments).  1 U of the 
/~-galactosidase activity  was expressed  arbitrarily as the activity that pro- 
duced 1 pmol of  4-methylumbelliferone  in 30 rain at 37"C. Under these con- 
ditions the B-galaetosidase  activity determined in COS-1 cells transfected 
with pSVLNOR or pSVLPH was '~50 U per 20 #g protein of cell lysate. 
The B-galaetosidase activity obtained in COS-1 cells into which pSVLNOR 
or pSVLPH was cotransfected  with pCltll0 ranged from 400 to 1,200 U 
per 20 ttg protein of ceU lysate, but the variation in the enzyme activity at 
each time point in one pulse-chase experiment was within 20% of the aver- 
age. The protein concentrations in extracts from human livers, COS-1 cells 
and E. coli JMI05 calls were measured by the Bradford method (Hammond 
and Kruger,  1988). 
Materials 
E-64C, a thiol protease inhibitor, was kindly donated by Research Labora- 
tories, Taisho Pharmaceutical Co., Ltd. (Saitama, Japan). COS-1 cells were 
provided by the Japanese Cancer Research Resources Bank (Tokyo, Japan). 
Male New Zealand white rabbits were purchased from Japan SLC,  Inc. 
(Hamamatsu,  Shizuoka,  Japan), and a nuclease-treated rabbit reticulocyte 
lysate for in vitro translation was prepared as described by Pelham and Jack- 
son (1976), A rabbit reticulocyte extract for in vitro protein degradation was 
prepared according to Fagan et al. (1986).  A reticulocyte  extract used in 
preliminary experiments for in vitro protein degradation was kindly donated 
by Drs. K. l~anaka  and A. Ichihara (Institute for Enzyme Research,  Univer- 
sity of Tokushima, Japan).  [ot-32p]dCTP (111 TBq/mmol) and Expre35S35S 
protein labeling mix (37 TBq/mmol) were obtained from DuPont-New 
England Nuclear (Boston, MA), L-[35S]methionine (37 TBq/mmol) from 
American Radiolabeled  Chemicals, Inc.  (St.  Louis,  MO),  125I-Protein A 
labeled with Bolton-Hunter reagent (1.77 MBq/ttg) from ICN Biochemicals 
Inc.  (Costa Mesa,  CA),  14C-methylated protein mixture (185 kBq/ml), 
DNA-labeling  system  and pAM19,  a  plasmid vector with SP6  and I"7 
promoters, from Amersham International  Pie (Buckinghamshire,  England), 
pSVL, a eukaryotic expression vector containing the SV-40 late promoter, 
pCHll0,  a  plasmid  coding  for  /3-galactosidase  activity,  pKK233-2,  a 
prokaryotic expression vector, and E. coli JMI05 from Pharmacia LKB Bio- 
technology (Tokyo, Japan), E.  coli DH5c~ from Life Technologies Orien- 
tal, Inc. (Tokyo, Japan), E. coli ER1458, a low strain, from New England 
Biolabs,  Inc.  (Beverly, MA), Ncol, EcoRI and other restriction enzymes 
from Toyobo Co., Ltd.  (Osaka,  Japan), a 443-bp HinfI-Hinfl fragment of 
human B-actin genomic DNA (~,Ha160) and PMSF from Wako Pure Chem- 
ical Industries Ltd. (Osaka, Japan), papstatin A and antipain from Peptide 
Institute,  Inc.  (Osaka,  Japan),  and leupeptin, aprotinln,  16S- and 23S- 
ribosomal RNAs from E. coli and hexokinase  from yeast from Boehringer 
Mannheim Yamanouchi,  Inc.  (Tokyo, Japan). 
Results 
RNA Blot Analysis 
On RNA blot analysis with poly(A)-rich RNA, a single band 
of SPT/AGT mRNA was observed in both control and patient 
liver. The size of  the patient's SPT/AGT mRNA was the same 
as that of the 1.7-kb SPT/AGT mRNA from control human 
liver.  On  densitometric  analysis,  the  level  of SPT/AGT 
mRNA in the patient's liver (Fig. 1, lane 1) was found to be 
approximately three times higher than that in control human 
liver (Fig.  1, lane 2). On the other hand, the level of 2.0-kb 
human ~-actin mRNA used as an internal standard was al- 
most the same among control and patient liver poly(A)-rich 
RNAs (Fig.  1, lanes 3 and 4). 
In Vitro Translation 
In vitro translation was carried out in a rabbit reticulocyte 
lysate system, and the products were analyzed by SDS/PAGE 
after immunoprecipitation with anti-rat mitochondrial SPT/ 
AGT serum or non-immune serum. As shown in Fig. 2, an 
immunoprecipitated band of approximately 43 kD was ob- 
served as the translation product from both the control hu- 
man liver (Fig. 2, lane 3) and patient liver (Fig. 2, lane 5) 
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scribed under Materials and Methods. Lanes I and 3, poly(A)-rich 
RNA from the PH 1 liver; lanes 2 and 4, control liver poly(A)-rich 
RNA.  Human  liver  (28S and  18S) and E.  coli (23S and  16S) 
ribosomal RNAs were used as size markers. 
poly(A)-rich RNAs. The immunological cross-reactivity of 
the translation product for human SPT/AGT with the anti-rat 
mitochondrial SPT/AGT antibody had been demonstrated 
previously (Nishiyama et al.,  1990), and the patient's liver 
SPT/AGT was also shown to react with the anti-rat mito- 
chondrial SPT/AGT antibody in this study.  The amount of 
the 43-kD product translated from the patient's liver poly(A)- 
rich RNA was even higher than that from the control. 
Cell-free translation was also carried out with RNA syn- 
thesized in vitro from the T7 RNA polymerase promoter in 
SPT/AGT cDNA clones isolated from control human liver 
(pHsptl2)  and the patient's  liver (pHOspt2).  The transla- 
tion products from the synthesized RNAs reacted with the 
anti-rat mitochondrial SPT/AGT antibody (Fig. 2, lanes  7 
and 9) and have the same molecular mass as that of the in 
vitro translation product from liver poly(A)-rich RNA. We 
previously  showed  that  the  isolated  clones,  pHsptl2  and 
pHOspt2, have a cDNA insert which encompasses the whole 
coding region of human SPT/AGT mRNA, and this coding 
region encodes a protein of  approximately 43 kD (Nishiyama 
et al.,  1990,  1991).  Therefore, the results of the in  vitro 
translation suggest that the same translation initiation ATG 
codon defines an open reading frame of 392 codons in both 
normal and patient SPT/AGT mRNA. In addition, RNA syn- 
thesized from pHOspt2 directed the in vitro translation at 
least as effectively as  RNA  synthesized from pHsptl2,  as 
judged from the time course of translation and the effect of 
the amount of RNA used (data not shown). These results to- 
gether  suggested  that  the  patient's  SPT/AGT-mRNA  was 
Figure 2. In vitro translation. The experimental procedures are de- 
scribed under Materials and Methods. Cell-free translation was per- 
formed without exogenous mRNA (lanes 1 and 2), with poly(A)- 
rich RNA isolated from a control liver (29-yr-old woman who died 
of a malignant lymphoma) (lanes 3 and 4) or the liver of the PH 1 
patient (lanes 5 and 6), or with capped mRNA synthesized using 
T7 RNA polymerase from SPT/AGT cDNA clones isolated from 
a control human liver (pHspt12) (lanes 7and 8) or the patient's liver 
(pHOspt2) (lanes 9 and 10). The translation products were reacted 
with nonimmune serum (even-numbered lanes) or anti-rat mito- 
chondrial SPT/AGT serum (odd-numbered lanes). The molecular 
size markers (lane M) were 14C-labeled myosin (200 kD), phos- 
phorylase b (92.5 kD), BSA (69 kD), ovalbumin (46 kD), carbonic 
anhydrase (30 kD), and lysozyme (14.3 kD) from Amersham Inter- 
national Plc. (SPTm, rat mitochondrial SPT/AGT). 
translatable.  This  suggestion  was  also  supported  by  the 
results  from pulse labeling  in  COS  cells and E.  coli  de- 
scribed below. It was thus indicated that SPT/AGT had been 
synthesized in the patient's liver at least as effectively as in 
the control liver. 
Western Blot Analysis and Immunoprecipitation of 
Human SPT/AGT 
Despite the suggestion that the mutant SPT/AGT had been 
synthesized in the patient's liver, Western blot analysis car- 
fled out with not only the anti-rat mitochondrial SPT/AGT 
antibody but also the anti-human SPT/AGT antibody failed 
to detect the mutant SPT/AGT, when 10/~g protein of extract 
from the patient's liver was subjected to analysis (Fig. 3, lane 
3). The mutant SPT/AGT was detectable when as much as 
500/~g protein of the liver extract was subjected to Western 
blot anlysis (Fig. 3, lane 9). In contrast, a single band of 43 
kD was clearly observed for the control human liver (Fig. 
3, lane 2) when 10 ftg protein of liver extract was applied. 
When 500/zg protein of  the control liver extract was applied, 
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as described under Materials  and Methods, except that 500/~g pro- 
tein of liver extracts was subjected to the analysis where indicated. 
Blots were probed with a rabbit antibody raised against normal hu- 
man SPT/AGT. Signals  were developed  using t25I-labeled protein 
A from Staphylococcus aureus.  20 ng protein of purified  human 
SPT/AGT (lane 1 ), 10/~g protein of a sonicated  liver extract from 
a 29-yr-old control subject (lane 2) and the PH 1 patient  (lane 3), 
100 tzg protein of a COS 1 cell lysate transfected  with pSVLNOR 
(lane 4) and pSVLPH (lane 5), and 37.5 #g protein of a sonicated 
extract of E. coli  JM105 ceils transformed with pKKNOR (lane 6) 
and pKKPH (lane  7) were analyzed by SDS/12%  PAGE. In lanes 
8 and 9, 500/~g protein of the liver extracts  from the control and 
the PH 1 patient was applied,  respectively.  The Western blot ana- 
lyzes of 10 #g (lanes 2 and 3) and 500 #g (lanes 8 and 9) liver ex- 
tracts were carried out in separate experiments.  The molecular size 
markers were phosphorylase b (97.4  kD), BSA (66 kD), ovalbumin 
(45 kD), glyceraldehyde  phosphate dehydrogenase  (36 kD), car- 
bonic anhydrase (29 kD), and trypsinogen (24 kD) from Sigma Im- 
munochemicals (St.  Louis, MO). 
the 43-kD band of normal human SPT/AGT became gigantic 
(Fig. 3, lane 8). The bands corresponding to normal and pa- 
tient SPT/AGT (Fig.  3, lanes 8 and 9) were cut out and the 
radioactivity was measured. The radioactivity of the normal 
SPT/AGT band was 35 times higher than that of the patient's 
SPT/AGT. 
In  another  experiment,  COS-1  cells  transfected  with 
pSVLNOR or pSVLPH  were  cultured  for 48  h  and  then 
pulse  labeled  with  [3sS]methionine/cysteine  for 20 rain.  A 
cell lysate was then prepared and subjected to Western blot 
analysis. The COS-1 ceils transfected with pSVLPH synthe- 
sized the immunoprecipitable 43-kD protein (SPT/AGT) as 
effectively as the cells transfected with pSVLNOR, as judged 
on pulse labeling with [35S]methionine/cysteine, but no dis- 
cernible amount of the mutant SPT/AGT was accumulated 
in the cells, while normal SPT/AGT was distinctly detectable 
(Fig. 3, lanes 4 and 5). Likewise, no accumulation of  the mu- 
tant SPT/AGT was observed in E. coli JM105 cells bearing 
pKKPH  (Fig.  3,  lanes  6  and  7).  Transformed  E.  coli 
ER1458, a Ion- strain, also failed to accumulate discernible 
amount of the mutant SPT/AGT, as judged by immunoper- 
oxidase method (data not shown). Misfolded proteins often 
Figure 4. Immunoprecipitation of  liver SPT/AGT. The immunopre- 
cipitation procedures are described under Materials  and Methods. 
Sonicated liver extracts  (6 mg protein each) from a 29-yr-old con- 
trol subject  (lanes 2 and 3) and the PH 1 patient  (lanes  4 and 5) 
were first incubated  with 40 t~l of 10%  (wt/vol) Pansorbin cells in 
a final vol of 340/~1. After centrifugation,  supernatants  were im- 
munoreacted with 50 t~l of anti-human SPT/AGT serum (lanes 3 
and 5) or nonimmune serum (lanes 2 and 4), and then immunopre- 
cipitated  with 40 #1 of 10% (wt/vol) Pansorbin cells. The immune 
complexes adsorbed on Pansorbin cells were subjected to SDS/12 % 
PAGE, followed by Coomassie brilliant blue R-250 staining. When 
100 t~l of 10% (wt/vol) Staphylosorb was used for immunoprecipi- 
tation,  the result was the  same as that obtained with Pansorbin 
cells,  except that nonspecific  adsorption on Pansorbin was slightly 
lower than that on Staphylosorb.  The molecular size markers (lane 
M) were those given in the legend to Fig.  3.  Lane 1,  7.5 ~g of 
purified  human SPT/AGT. (hSP~, human SPT/AGT). 
form insoluble aggregates, especially when overproduced in 
prokaryotic ceils, but in experiments with E. coli both nor- 
mal and mutant SPT/AGTs were expressed only to a  level 
which was detectable by Western blot analysis. In addition, 
when  transformed  E.  coli  (JM105  and  ER1458)  was  dis- 
solved in SDS-gel loading buffer without sonlcation and sub- 
jected to Western blot analysis without centrifugation,  the 
same results  as those with  sonlcated  supernatants  (Fig.  3, 
lanes  6 and  7) were obtained.  In experiments  with COS-1 
cells, no aggregates of the mutant SPT/AGT were detectable 
immunocytochemically.  These  results  suggested,  although 
not proved, that the failure in detecting the immunoreactive 
mutant SPT/AGT was not entirely due to failure to extract 
the enzyme. 
We also tried to recover the mutant SPT/AGT from a sonic 
extract of the patient's liver by reaction with the anti-human 
SPT/AGT antibody in solution.  SPT/AGT was immunopre- 
The Journal of Cell Biology, Volume 123,  1993  1242 Figure 3.  Protein A-gold immunocytochemistry of SPT/AGT in livers. The experimental procedures are described under Materials and 
Methods. Anti-human SPT/AGT serum was used for a, c, and e, and non-immune serum for b, d, and f. (a and b) Sections from the 
liver obtained on open biopsy from a 57-yr-old man suffering from gastric cancer; (c and d) sections from the liver obtained on autopsy 
5-h postmortem from a 29-yr-old control subject; (e and f) sections from the liver of the PH  1 patient. The liver of the PH  1 patient 
was obtained on autopsy 5-h postmortem. (M, mitochondria; P, peroxisomes). Bars, 0.5/~m. 
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ered as the 43 kD product (Fig. 4, lane 3), but no specific 
band of 43 kD was detected when the sonic extract of the pa- 
tient's liver was subjected to immunoprecipitation (Fig. 4, 
lane 5). These findings indicated that the patient's liver con- 
tained an extremely low level of the mutant SPT/AGT, prob- 
ably due to rapid degradation. 
Immunocytochemical Staining of SPT/AGT in Control 
and Patient Liver 
The  intracellular  localization  of mutant  SPT/AGT in  the 
patient's  liver  was  studied  immunocytochemically  using 
anti-human  SPT/AGT  serum  and  anti-rat  mitochondrial 
SPT/AGT serum.  Fig.  5  shows  the  results  obtained with 
anti-human  SPT/AGT serum.  Quantitative analysis of the 
labeling density was carried out in a separate experiment in- 
volving anti-rat mitochondrial SPT/AGT serum. 
In a fresh liver preparation, gold particles showing cata- 
lase were present exclusively in peroxisomes. Other cell or- 
ganelles such as mitochondria and ER were consistently al- 
most  negative  for  catalase.  The  labeling  densities  (gold 
particles//~m  2) in mitochondria and the cytoplasmic matrix 
were calculated to be 0.39%  and 0.48%  of that in peroxi- 
somes, respectively (Table I). When sections from the same 
preparation were incubated with either anti-rat mitochon- 
drial  SPT/AGT  serum  or  anti-human  SPT/AGT  serum, 
heavy labeling with gold particles was observed almost ex- 
clusively in peroxisomes. Few gold particles were present in 
mitochondria  and  the  cytoplasmic matrix  (Fig.  5  a,  and 
Table I). 
In postmortem preparations of liver, preservation of the 
hepatocyte ultrastructure was considerably poor, most mito- 
chondria being markedly swollen and having lost their cris- 
tae.  Some mitochondria contained electron-dense material 
(Fig. 5, c-f). Most peroxisomes showed partial membrane 
disruption.  The  intact  region  of  the  membrane  was  as- 
sociated with the endoplasmic reticulum membrane (Fig. 5, 
c-e). The peroxisomal matrix aggregated to form a floccu- 
lent configuration which was never observed in the peroxi- 
somes of a fresh liver preparation. Nevertheless, gold parti- 
cles  showing  the  antigenic  sites  for catalase were almost 
confined to peroxisomes in autopsy liver preparations from 
patients who died of other diseases (Table I). Gold particles 
Table L Labeling Densities for Catalase and SPT/AGT in 
Mitochondria and Cytoplasmic Matrix Relative to Those 
in Peroxisomes 
Catalase  SPT/AGT 
Cytoplasmic  Cytoplasmic 
Mitochondria  matrix  Mitoehondria  matrix 
(%)  (%) 
Biopsy  0.39  0.48  0.59  0.49 
(control) 
Postmortem  3.0  2.4  15.0  8.5 
(control) 
Postmortem  1.4  1.3  25.6  14.4 
(PH 1) 
Labeling densities (gold particles//~m  2) are expressed as percentages of the den- 
sity in peroxisomes of each liver sample. Values are the mean of 10 determina- 
tions on different electron micrographs of hepatocytes in the same liver specimen. 
Experimental procedures  are described under Materials and Methods. 
Figure  6.  Pulse-chase  experiment  with  COS-1 ceils.  The  ex- 
perimental procedures are described under Materials and Methods. 
(a) COS-1 cells were labeled with [35S]methionine/cysteine for 20 
min.  At time zero,  unlabeled  L-methionine  and L-cysteine were 
added in excess, and then the incubation was continued for the indi- 
cated periods. The COS-1 cell lysate (850 #g protein) was first in- 
cubated with 50 ~tl of 10 % (wt/vol) Staphylosorb in a final vol of 
350 tzl. After centrifugation,  the supernatant was immunoreacted 
with 10/~1 of  anti-human SPT/AGT serum and then immunoprecip- 
itated with 50 tzl of 10% (wt/vol) Staphylosorb. The immune com- 
plex was analyzed by SDS/12 % PAGE. This experiment was carded 
out twice (in one experiment all procedures  after the transfection 
were performed in triplicate) with almost identical results. The mo- 
lecular size markers were those given in the legend to Fig. 2. (Ar- 
rowhead) A minor band with a molecular mass of approximately 
37 kD. (b) Autoradiograms  were scanned with a Shimadzu high- 
speed TLC scanner CS-920 (Shimadzu Corp., Kyoto, Japan) and 
the densitometric readings at 595 nm are expressed as percentages 
of the density at time zero. (o) Normal human SPT/AGT; (o) mu- 
tant SPT/AGT of the PH 1 patient. Each point represents the aver- 
age of triplicate  determinations. 
showing  the  SPT/AGT  antigens  sites  were  also  detected 
mainly in peroxisomes, but a  few particles were scattered 
outside the peroxisomes (Fig. 5 c). The labeling densities of 
SPT/AGT in mitochondria and the cytoplasmic matrix were 
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In the liver of the PH 1 patient, in which gold labels for cata- 
lase were concentrated in the peroxisomes (Table I), gold 
particles showing SPT/AGT antigenic sites were scarce on 
the whole but were detected mainly in peroxisomes (Fig. 5 
e). The labeling density relative to that in peroxisomes were 
approximately 25.6% in mitochondria and 14.4% in the cy- 
toplasmic matrix.  The mitochondrial labeling density was 
higher than the cytoplasmic background, but the ratio of the 
labeling density in mitochondria to that in the cytoplasmic 
matrix was about the same in the control autopsy sample and 
the PH 1 sample. No gold particles were noted in any of the 
control sections in which non-immune serum was used in- 
stead of anti-SPT/AGT serum (Fig. 5, b, d, and f). The im- 
munocytochemical analysis suggested that the mutant SPT/ 
AGT had been synthesized in the patient's liver, predestined 
to be localized in peroxisomes. It also appeared from the 
experiment that  SPT/AGT leaks  from peroxisomes more 
readily than catalase during the postmortem cell destruction 
(c.f.  Table I).  Several peroxisomal matrix enzymes have 
been shown to vary in how easily they leak out when isolated 
rat liver peroxisomes are subjected to mechanical damages 
(Alexon et al.,  1985). 
Degradation Rate of Normal and Patient SPT/AGT 
The degradation rate of 35S-labeled SPT/AGT was analyzed 
in an attempt to reveal whether or not the low content of im- 
munoreactive SPT/AGT in this PH 1 patient is due to insta- 
bility of the mutant SPT/AGT in the cells. The COS-1  ceils 
and E.  coli JM105 used in this experiment did not produce 
SPT/AGT by themselves.  In  this  experiment, pSVLNOR 
or pSVLPH was  cotransfected into  the  COS-1  cells  with 
pCHll0,  a  plasmid coding for ~-galactosidase activity, to 
monitor the efficiency  of the transient expression. The/~-galac- 
tosidase activity in cell lysate was almost the same between 
the COS-1  cells transfected with pSVLNOR and pSVLPH, 
indicating that pSVLNOR and pSVLPH were almost equally 
transfected. As shown in Fig. 6, the pulse-chase experiments 
with COS-1 cells demonstrated that normal SPT/AGT is rel- 
atively stable and is degraded with an apparent half-life of 
approximately 11 h.  However, the protein concentration in 
COS-1  cell lysate increased with time,  and after 24 h,  it 
reached a 1.5 to 1.9 times higher level than that at time zero. 
It thus appears that the pulse-labeled SPT/AGT was diluted 
by the growth and multiplication of COS-1  cells with time 
and the half-life of normal SPT/AGT was underestimated. 
On the other hand,  the decay of the patient's SPT/AGT in 
COS-1 cells was distinctly rapid. Approximately 90% of the 
labeled SPT/AGT was lost within 6 h, with an apparent half- 
life of approximately 1.8 h, and after 24 h, the labeled 43-kD 
band was no longer detectable. During the degradation of  the 
patient's  SPT/AGT,  no immunoprecipitable products  with 
higher molecular masses, such as the conjugates with other 
proteins, were detectable on SDS-PAGE analysis, but a mi- 
nor band with a  smaller molecular mass  (37 kD) was  ob- 
served throughout the incubation period, in addition to the 
major band (43 kD) of normal and patient SPT/AGTs (Fig. 
6 a, arrowhead). The 37-kD protein appeared to be derived 
through translation from a downstream AUG codon rather 
than a degradation product of the 43-kD SPT/AGT. 
The pulse-chase experiment with transformed E. coli also 
demonstrated the rapid decay of the mutant SPT/AGT. As 
shown in  Fig.  7,  an almost equal amount of immunopre- 
cipitable SPT/AGT was synthesized during 5-min pulse la- 
beling  with  [35S]methionine  in  both  E.  coli  JM105  cells 
bearing pKKNOR and pKKPH.  Thereafter, normal  SPT/ 
AGT was  stable and rather increased about 2.5-fold in the 
course of chase incubation  for unknown  reasons.  On  the 
other hand,  pulse-labeled patient's  SPT/AGT was  rapidly 
degraded, with an almost 60% decrease during the first 1 h. 
Tanaka et al.  (1983)  demonstrated that two distinct non- 
lysosomal ATP-dependent proteolytic systems exist in retic- 
ulocytes; one requires ubiquitin and the other is independent 
of ubiquitin. We then examined degradation of the patient's 
SPT/AGT in a rabbit reticulocyte extract system with special 
attention to the ATP-dependency (Fig. 8).  [3~S]labeled nor- 
Figure 7. Pulse-chase experi- 
ment with E. coli JM105. The 
experimental  procedures  are 
described under Materials and 
Methods.  (a)  Transformed 
E.  coli  JM105 had  been  la- 
beled  with  [35S]methionine 
for  5  min.  At  time  zero, 
unlabeled  L-methionine  was 
added in excess, and then the 
incubation was continued for 
the times indicated. The soni- 
cated extract (100 #1) was first 
incubated with 50 #1 of 10% 
(wt/vol) Staphylosorb  in a final 
vol of 350 #1. After centrifu- 
gation, the supernatant  was im- 
munoreacted  with  10  #1  of 
anti-human SPT/AGT serum, 
followed  by immunoprecipita- 
tion with 50 #1 of 10% (wt/vol) Staphylosorb. The immune complex was analyzed by SDS/12  % PAGE. Three separate experiments were 
performed with essentially the same results. The molecular size markers were those given in the legend to Fig. 2. (b) Autoradiograms 
were scanned with a Shimadzu high-speed TLC scanner CS-920. The relative densitometric readings at 595 nm were plotted. (o) Normal 
SPT/AGT; (o) mutant SPT/AGT of the PH 1 patient. Each point represents the average of three separate experiments. 
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reticulocyte extract.  3sS-labeled normal human SPT/AGT (a) and 
the patient's SPT/AGT (b) were synthesized from respective cDNAs 
in a T7 RNA polymerase-retieulocyte  lysate system, and subjected 
to the reaction with reticulocyte extract for protein degradation in 
the presence or absence of ATP at 37°C for the indicated periods. 
Detailed  experimental  procedures  are given under  Materials  and 
Methods. ATP (+): The reaction for degradation was carried out 
in the presence of 5 mM ATP. ATP (-): 20 mM 2-deoxyglueose 
and 25 U/ml of hexokinase were added instead of ATP to deplete 
ATP from the reaction mixture. The molecular size markers were 
those given in the legend to Fig. 2. 
mal and mutant human SPT/AGTs synthesized from respec- 
tive cDNAs were incubated with rabbit reticulocyte extract 
for protein degradation in the presence of ATP or under con- 
ditions of ATP depletion established by adding 2-deoxyglu- 
cose and hexokinase instead of ATP.  Normal human SPT/ 
AGT was stable and almost all the 3~S-labeled enzyme was 
retained after 120-min incubation in either the presence or 
the absence of ATP. In contrast, the patient's SPT/AGT de- 
creased to a very low level after 90-120-min incubation for 
degradation in the presence of ATP, and the degradation was 
distinctly dependent on ATP. 
Discussion 
This study is the first to provide information as to the molec- 
ular mechanism responsible for the SPT/AGT deficiency in 
primary hyperoxaluria type I due to rapid degradation of mu- 
tant SPT/AGT.  The PH  1 patient presented had decreased 
SPT activity  (~1%  of  the normal level)  and his SPT/AGT 
gene  had  a  homozygous point  mutation in  the  coding region, 
as demonstrated previously  (Nishiyama et  al.,  1991).  In  an 
attempt to purify the mutant SPT/AGT  from the patient's 
liver  by the same procedures as those  described previously 
for  normal human SPT/AGT  (Nishiyama et  al.,  1990),  pro- 
tein(s) with the low SPT  activity  behaved  in both phos- 
phocellulose  and hydroxylapatite  column chromatographics 
quite differently  from  normal  SPT/AGT.  In addition, no 
band with a molecular mass of  43 kD was detected  in  frac- 
tions  with the  SPT activity  on SDS/PAGE  analysis  (data  not 
shown).  Since some other  aminotransfcrascs  are known to 
exhibit  weak SPT activity,  it  is  highly  possible  that  the low 
SPT activity  detected  in  the  patient's  liver  is  not  entirely  that 
of  the  mutant SPT/AGT. Western blot  analysis  performed in 
this  study  demonstrated  that  not only the activity  (<1% of 
normal) (Nishiyama et  al.,  1991)  but also  the immunoreac- 
tivc  protein  (*2.8  %  of  normal) was severely  decreased (c.  f. 
Fig.  3).  RNA  blot  analysis  and in  vitro  translation  of  mRNA 
from the  patient's  liver  indicated  that  the  enzyme deficiency 
is duc to neither  a defect  in transcription  of  the SPT/AGT 
gene nor one in  the translation  of  the message. Estimation 
of the decay rate  of SPT/AGT  in COS-I  cells  and E.  coli 
JMI05 revealed  that  the  patient's  SPT/AGT  was unstable  in 
the cells  and rapidly degraded as compared  with normal 
SPT/AGT.  In COS-I  cells,  the half-life  of the paticnfs 
SPT/AGT  was about 6 times shorter  than that  of normal 
SPT/AGT  (c.f.  Fig. 6 b). The patient's  SPT/AGT  was also 
degraded rapidly  in  vitro  in  rabbit  reticulocyte  extract  in  an 
ATP-dependent manner. From these  results,  we suspect  that 
the  enzyme defect  in  this  patient  is  accounted for,  at  least  in 
part,  by  the  instability  and intracellular  rapid  degradation  of 
the  mutant SPT/AGT. This is  likely  to  be  due to  a  point  mu- 
tation  in  the  patient's  SPT/AGT gcnc  leading  to  a  substitution 
of  Scr to Pro at residue  205 of  SPT/AGT. 
Nonlysosomal,  energy-  and ubiquitin-dcpendent  processes 
arc  supposed to  be  involved  in  selective  removal of  unneces- 
sary  proteins  with a rapid  turnover,  such as  cyclin  (Glotzcr 
ct  al.,  1991)  and c-Mos (Nishizawa ct  al.,  1992) which arc 
closely related  to cell  cycle  progression, and of abnormal 
proteins generated in cells  (Rechsteiner, 1991). In these 
processes,  ubiquitin  serves  as  a  signal  for  degradation  of  pro- 
teins,  and a  novel  ATP-dcpendent protease  complex with an 
apparent sedimentation cocIiicient  of  26S (26S proteasomc) 
appears to bc responsible  for recognition  of ubiquitinated 
proteins and their  subsequent ATP-dependcnt  degradation 
(Matthews et  al.,  1989; Goldberg,  1992). In  this  study,  the 
degradation of  the mutant SPT/AGT  in  reticulocyte  extract 
was clearly  ATP dependent. However, no immunoreactive 
products with higher molecular  masses,  such as the con- 
jugates  with ubiquitin,  wcrc detectable  during the  course of 
its degradation in either the transfected COS ceils or the in 
vitro reticulocyte lysate system, under the conditions used. 
Although ubiquitin-dependency of degradation of the mutant 
SPT/AGT in eukaryotic cells has to be further examined be- 
fore  conclusion,  it  is  worthwhile  to  notice  that  ornithine 
decarboxylase was recently found to be degraded ATP and 
antizyme dependently by the 26S proteasome without ubi- 
quitination  (Murakami et al.,  1992).  The observation that 
the patient's SPT/AGT was also degraded in E.  coli would 
be of great interest, if it means that the mutant enzyme is rec- 
ognized as an abnormal protein to be degraded in the two 
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yet studied in detail the degradation in E. coli, we would like 
to reserve any discussion on the bacterial degradation  before 
elucidation of the underlying mechanism. 
With respect to the degradation  of the mutant  SPT/AGT 
in vitro, no degradation occurred in reticulocyte lysate for 
translation, probably because, at least in part, the lysate con- 
tained 40/~M heroin. In reticulocyte lysate, heroin appears 
to promote protein synthesis by preventing  the inactivation 
of a specific factor (eif-2) through the mediation of a heme- 
dependent kinase (Datta et al., 1978;  Ranu et al., 1978;  Ta- 
hara et al., 1978), but hemin has been also shown to inhibit 
the  ATP-dependent  degradation  of abnormal  and  normal 
proteins.  50% inhibition  of the degradation  of [t'CH3](apo)- 
hemoglobin,  [m25I]BSA, and  [3H]casein  has  been  achieved 
by  12,  25,  and 40  #M  hemin,  respectively  (Etlinger and 
Goldberg, 1980;  Haas and Rose, 1981; Tanaka et al., 1983). 
In the present study, the hemin concentration in the reaction 
mixture for degradation of 3sS-labeled  SPT/AGT was low- 
ered to 0.8/zM by minimizing the carry-over from the in vitro 
translation  mixture. 
It is known that peroxisomal proteins are synthesized on 
free polysomes,  released into the cytosol,  and then trans- 
ported into peroxisomes (Lazarow and Fujiki, 1985). On the 
other hand, functional proteolytic systems such as the ATP- 
dependent 26S proteasome have been found in the cytosol 
(Tanaka et al., 1992), but proteolytic systems in peroxisomes 
have not been clearly demonstrated.  In the case of the PH 
1 patient,  immunocytochemically  detected SPT/AGT anti- 
genic sites were scarce on the whole but were concentrated 
predominantly in peroxisomes, suggesting that mutant SPT/ 
AGT retained the capacity of targeting the proper organelle. 
However, it still remains to be clarified where the mutant en- 
zyme  is  degraded  rapidly,  i.e.,  in the  cytosol  during  the 
transport  to peroxisomes or in the peroxisomes after trans- 
port. Preliminary results obtained to date demonstrated the 
mutant SPT/AGT degradation  in the cytosol of transfected 
COS cells, although  they have not yet excluded a possibility 
that the mutant protein is also degraded in peroxisomes. If 
the degradation occurs only or mainly in the cytosol, then 
it  should be  answered whether the mutant  enzyme  is de- 
graded during the normal transport  into peroxisomes or is 
degraded rapidly partly because the enzyme stays longer in 
the cytosol due to impaired or inefficient transport.  Kinetic 
studies on transport  into peroxisomes of the mutant  SPT/ 
AGT in comparison with the kinetics of its degradation  will 
give us an answer, but for this purpose characterization  of 
the proteolytic system(s) responsible for the degradation  of 
the mutant  SPT/AGT is indispensable as a prerequisite. 
Another major question  still remains to be answered is 
whether or not the mutant SPT/AGT has enzyme activity and 
what kind of conformational change is caused by the Ser to 
Pro substitution  at residue 205. We have been especially anx- 
ious  for the purification of the  mutant  enzyme,  but since 
E.  coli transformed with the recombinant plasmid, pKKPH 
did not accumulate the mutant SPT/AGT, we have not been 
successful at the purification. Continued trials to purify the 
mutant  SPT/AGT are under way. 
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